香港股市 將在 24 分鐘 開市
  • 恒指

    22,072.18
    +229.85 (+1.05%)
     
  • 國指

    7,560.40
    +135.48 (+1.82%)
     
  • 上證綜指

    3,284.92
    +29.25 (+0.90%)
     
  • 道指

    34,092.96
    +6.92 (+0.02%)
     
  • 標普 500

    4,119.21
    +42.61 (+1.05%)
     
  • 納指

    11,816.32
    +231.77 (+2.00%)
     
  • Vix指數

    17.87
    -1.53 (-7.89%)
     
  • 富時100

    7,761.11
    -10.59 (-0.14%)
     
  • 紐約期油

    77.06
    +0.65 (+0.85%)
     
  • 金價

    1,968.30
    +25.50 (+1.31%)
     
  • 美元

    7.8397
    -0.0004 (-0.01%)
     
  • 人民幣

    0.8592
    +0.0001 (+0.01%)
     
  • 日圓

    0.0609
    +0.0003 (+0.53%)
     
  • 歐元

    8.6400
    +0.0272 (+0.32%)
     
  • Bitcoin

    24,128.55
    +1,028.00 (+4.45%)
     
  • CMC Crypto 200

    549.70
    +307.02 (+126.51%)
     

Becton Dickinson's FY23 Guidance Trails Wall Street View Reflecting Foreign Currency Impact

  • Becton Dickinson and Co (NYSE: BDX) reported Q4 FY22 revenues of $4.76 billion, down 1.8% Y/Y (up 2.3% on a currency-neutral basis), slightly better than the consensus of $4.72 billion.

  • Revenue was driven by base revenue growth of 4.2% as reported, 8.6% currency-neutral.

  • Medical segment sales increased 5.8% Y/Y to $2.38 billion.

  • Life Sciences segment sales declined 15.9% Y/Y to $1.29 billion, reflecting the decline in COVID-only testing revenues.

  • Interventional segment revenues grew 2.4% Y/Y to $1.09 billion.

  • Operating income increased from $380 million to $490 million, with the margin improving from 7.8% to 10.3%.

  • Adjusted EPS of $2.75, up from $2.15 a year ago, topping the consensus of $2.74.

  • Related Becton Dickinson Recalls Some Sterilization Containers Over Breached Quality.

  • Guidance: BD expects FY23 sales of $18.6-$18.8 billion versus the consensus of $19.37 billion.

  • Revenue guidance assumes base business currency-neutral revenue growth of 5.25%-6.25% and approximately $125-$175 million in COVID-19-only diagnostic testing revenues.

  • The foreign exchange would represent a reduction of approximately 450 basis points to total company revenue growth.

  • The company expects adjusted EPS of $11.85-$12.10 versus the consensus of $12.19.

  • Price Action: BDX shares closed lower by 0.55% at $218.29 on Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.